#statestreetglobal
statestreetglobal
838 views
5 Discussing
Hot
Latest
🚫🚫 Genuinely if Bera pops, nobody can say they weren’t warned—the dip is screaming ‘act now’ 🟢🚀 nobody ready for this
#NorthernTrust #SoFi #StateStreetGlobal #JamesPaulWarburg
$RUNE $ZRX $ZIL $BTG $REP $DOGE $LUNA
#NorthernTrust #SoFi #StateStreetGlobal #JamesPaulWarburg
$RUNE $ZRX $ZIL $BTG $REP $DOGE $LUNA
This been on my mind Allo heating up and timelines panicking—the dump is your opportunity to sneak in — why is nobody talking?? 📈📈📈 🟢🚀
#StateStreetGlobal #SendIt #LynAlden #HarmonicPatterns
$ADA $IOTA $GRT $BCH $XLM
#StateStreetGlobal #SendIt #LynAlden #HarmonicPatterns
$ADA $IOTA $GRT $BCH $XLM
State Street Pushes into Crypto as Eli Lilly Stock Slips on FDA Delay
Eli Lilly's stock price experienced a significant drop on January 15, 2026, after reports of an FDA review delay for its oral GLP-1 weight-loss pill, orforglipron. The new target action date for the drug's approval is reportedly April 10, 2026.
Simultaneously, State Street has launched a new institutional digital asset platform to support tokenization services and crypto custody.
State Street's Crypto Push
Platform Launch: State Street, the world's second-largest custody bank, has rolled out a new institutional digital asset platform.
Services: The platform moves beyond back-office support, offering wallet management, custody, cash products (tokenized deposits, stablecoins), and support for tokenized money market funds and ETFs.
Strategic Shift: This launch signifies a strategic move from experimentation to scalable solutions in the digital asset space, partnering with firms like Taurus for technology to help institutions embrace tokenization with confidence.
FDA Delay for Eli Lilly's GLP-1
Delayed Review: The FDA has extended the review period for Eli Lilly's promising oral obesity drug candidate, orforglipron.
Impact on Stock: Following the news, Eli Lilly (LLY) shares slipped nearly 5% on Thursday, January 15, 2026.
New Timeline: The internal regulatory documents suggest a target action date of April 10, 2026, pushing back previous expectations for a Q1 2026 approval. The company's CFO noted they are on track for a Q2 2026 approval.
#StateStreetGlobal
#crypto
#EliLilly
#FDAApproval
#StrategyBTCPurchase
Eli Lilly's stock price experienced a significant drop on January 15, 2026, after reports of an FDA review delay for its oral GLP-1 weight-loss pill, orforglipron. The new target action date for the drug's approval is reportedly April 10, 2026.
Simultaneously, State Street has launched a new institutional digital asset platform to support tokenization services and crypto custody.
State Street's Crypto Push
Platform Launch: State Street, the world's second-largest custody bank, has rolled out a new institutional digital asset platform.
Services: The platform moves beyond back-office support, offering wallet management, custody, cash products (tokenized deposits, stablecoins), and support for tokenized money market funds and ETFs.
Strategic Shift: This launch signifies a strategic move from experimentation to scalable solutions in the digital asset space, partnering with firms like Taurus for technology to help institutions embrace tokenization with confidence.
FDA Delay for Eli Lilly's GLP-1
Delayed Review: The FDA has extended the review period for Eli Lilly's promising oral obesity drug candidate, orforglipron.
Impact on Stock: Following the news, Eli Lilly (LLY) shares slipped nearly 5% on Thursday, January 15, 2026.
New Timeline: The internal regulatory documents suggest a target action date of April 10, 2026, pushing back previous expectations for a Q1 2026 approval. The company's CFO noted they are on track for a Q2 2026 approval.
#StateStreetGlobal
#crypto
#EliLilly
#FDAApproval
#StrategyBTCPurchase
Login to explore more contents